Jagsonpal Pharmaceuticals Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

Jagsonpal Pharmaceuticals heeft een totaal eigen vermogen van ₹2.0B en een totale schuld van ₹0.0, wat de schuld-eigenvermogensverhouding op 0% brengt. De totale activa en totale passiva bedragen respectievelijk ₹2.6B en ₹611.0M. De EBIT Jagsonpal Pharmaceuticals is ₹226.5M waardoor de rentedekking -2.9 is. Het heeft contanten en kortetermijnbeleggingen van ₹778.5M.

Belangrijke informatie

Verhouding schuld/eigen vermogen

₹0

Schuld

Rente dekkingsratio	-2.9x
Contant	₹778.45m
Aandelen	₹1.97b
Totaal verplichtingen	₹610.95m
Totaal activa	₹2.58b

Recente financiële gezondheidsupdates

Geen updates

Recent updates

Some Confidence Is Lacking In Jagsonpal Pharmaceuticals Limited's (NSE:JAGSNPHARM) P/E

Oct 14

There May Be Some Bright Spots In Jagsonpal Pharmaceuticals' (NSE:JAGSNPHARM) Earnings

May 27

There's Reason For Concern Over Jagsonpal Pharmaceuticals Limited's (NSE:JAGSNPHARM) Massive 27% Price Jump

Apr 30

A Look At The Fair Value Of Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM)

Apr 05

Investor Optimism Abounds Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM) But Growth Is Lacking

Feb 06

Estimating The Intrinsic Value Of Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM)

Jul 29

A Look At The Intrinsic Value Of Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM)

May 13

Does Jagsonpal Pharmaceuticals (NSE:JAGSNPHARM) Deserve A Spot On Your Watchlist?

Jul 05

A Look At The Fair Value Of Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM)

Jun 13

Jagsonpal Pharmaceuticals Limited's (NSE:JAGSNPHARM) 0.6% Dividend Yield Looks Pretty Interesting

Apr 19

Should You Be Adding Jagsonpal Pharmaceuticals (NSE:JAGSNPHARM) To Your Watchlist Today?

Mar 21

Jagsonpal Pharmaceuticals Limited's (NSE:JAGSNPHARM) Stock Is Going Strong: Have Financials A Role To Play?

Feb 08

The Attractive Combination That Could Earn Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM) A Place In Your Dividend Portfolio

Jan 08

Here's Why I Think Jagsonpal Pharmaceuticals (NSE:JAGSNPHARM) Is An Interesting Stock

Dec 21

Are Jagsonpal Pharmaceuticals's (NSE:JAGSNPHARM) Statutory Earnings A Good Reflection Of Its Earnings Potential?

Nov 30

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( ₹1.4B ) JAGSNPHARM } overtreffen de korte termijn passiva ( ₹469.9M ).

Langlopende schulden: De kortetermijnactiva JAGSNPHARM ( ₹1.4B ) overtreffen de langetermijnschulden ( ₹141.0M ).

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: JAGSNPHARM is schuldenvrij.

Schuld verminderen: JAGSNPHARM heeft geen schulden vergeleken met 5 jaar geleden, toen de schuld/eigen vermogen-ratio 4.1% was.

Schuldendekking: JAGSNPHARM heeft geen schulden en hoeft daarom niet gedekt te worden door de operationele kasstroom.

Rentedekking: JAGSNPHARM heeft geen schulden, dus de dekking van rentebetalingen is geen probleem.

Jagsonpal Pharmaceuticals Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

Belangrijke informatie

Recente financiële gezondheidsupdates

Recent updates

Jagsonpal Pharmaceuticals Limited to Report Q2, 2025 Results on Oct 23, 2024

Some Confidence Is Lacking In Jagsonpal Pharmaceuticals Limited's (NSE:JAGSNPHARM) P/E

Investor sentiment improves as stock rises 16%

Upcoming dividend of ₹5.00 per share

Jagsonpal Pharmaceuticals Limited, Annual General Meeting, Sep 18, 2024

First quarter 2025 earnings released: EPS: ₹1.94 (vs ₹2.85 in 1Q 2024)

Jagsonpal Pharmaceuticals Limited to Report Q1, 2025 Results on Aug 07, 2024

Investor sentiment improves as stock rises 16%

New minor risk - Market cap size

There May Be Some Bright Spots In Jagsonpal Pharmaceuticals' (NSE:JAGSNPHARM) Earnings

Full year 2024 earnings released: EPS: ₹8.49 (vs ₹10.20 in FY 2023)

There's Reason For Concern Over Jagsonpal Pharmaceuticals Limited's (NSE:JAGSNPHARM) Massive 27% Price Jump

Investor sentiment improves as stock rises 16%

A Look At The Fair Value Of Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM)

Now 20% undervalued after recent price drop

Investor Optimism Abounds Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM) But Growth Is Lacking

New minor risk - Market cap size

Third quarter 2024 earnings released: EPS: ₹1.48 (vs ₹2.97 in 3Q 2023)

Jagsonpal Pharmaceuticals Limited Announces Chief Financial Officer Changes

Jagsonpal Pharmaceuticals Limited to Report Q3, 2023 Results on Feb 01, 2024

Now 20% undervalued after recent price drop

Now 23% undervalued after recent price drop

Now 20% undervalued after recent price drop

Second quarter 2024 earnings released: EPS: ₹2.84 (vs ₹3.97 in 2Q 2023)

Jagsonpal Pharmaceuticals Limited to Report Q2, 2024 Results on Nov 03, 2023

Upcoming dividend of ₹5.00 per share at 1.1% yield

Jagsonpal Pharmaceuticals Limited, Annual General Meeting, Aug 31, 2023

First quarter 2024 earnings released: EPS: ₹2.85 (vs ₹0.14 in 1Q 2023)

Estimating The Intrinsic Value Of Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM)

Jagsonpal Pharmaceuticals Limited to Report Q1, 2024 Results on Aug 02, 2023

Full year 2023 earnings released: EPS: ₹10.20 (vs ₹7.48 in FY 2022)

Jagsonpal Pharmaceuticals Limited Recommends Dividend for the Financial Year Ended March 31, 2023

Investor sentiment improves as stock rises 15%

Jagsonpal Pharmaceuticals Limited Announces Appointment of Abhishek Joshi as Company Secretary and Compliance Officer

Third quarter 2023 earnings released: EPS: ₹2.97 (vs ₹2.06 in 3Q 2022)

Jagsonpal Pharmaceuticals Limited Announces Executive Changes

Investor sentiment improved over the past week

High number of new and inexperienced directors

Second quarter 2023 earnings released: EPS: ₹3.97 (vs ₹2.79 in 2Q 2022)

High number of new and inexperienced directors

Jagsonpal Pharmaceuticals Limited, Annual General Meeting, Sep 14, 2022

First quarter 2023 earnings released: EPS: ₹0.14 (vs ₹2.61 in 1Q 2022)

Jagsonpal Pharmaceuticals Limited to Report Q1, 2023 Results on Aug 09, 2022

High number of new and inexperienced directors

Full year 2022 earnings released: EPS: ₹748 (vs ₹6.51 in FY 2021)

Jagsonpal Pharmaceuticals Limited to Report Q4, 2022 Results on May 30, 2022

Investor sentiment improved over the past week

A Look At The Intrinsic Value Of Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Jagsonpal Pharmaceuticals Limited Announces Resignation of Sanjiv Kumar Dudeja as Chief Financial Officer

Investor sentiment improved over the past week

Upcoming dividend of ₹4.00 per share

Second quarter 2022 earnings released: EPS ₹2.79 (vs ₹1.53 in 2Q 2021)

Upcoming dividend of ₹1.00 per share

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

First quarter 2022 earnings released: EPS ₹2.61 (vs ₹0.96 in 1Q 2021)

Investor sentiment improved over the past week

Does Jagsonpal Pharmaceuticals (NSE:JAGSNPHARM) Deserve A Spot On Your Watchlist?

Full year 2021 earnings released: EPS ₹6.51 (vs ₹3.00 in FY 2020)

Investor sentiment improved over the past week

A Look At The Fair Value Of Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Jagsonpal Pharmaceuticals Limited's (NSE:JAGSNPHARM) 0.6% Dividend Yield Looks Pretty Interesting

Should You Be Adding Jagsonpal Pharmaceuticals (NSE:JAGSNPHARM) To Your Watchlist Today?

New 90-day high: ₹93.35

Investor sentiment improved over the past week

Jagsonpal Pharmaceuticals Limited's (NSE:JAGSNPHARM) Stock Is Going Strong: Have Financials A Role To Play?

Jagsonpal Pharmaceuticals Limited to Report Q3, 2021 Results on Feb 12, 2021

The Attractive Combination That Could Earn Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM) A Place In Your Dividend Portfolio

Insider recently bought ₹1.3m worth of stock